Skip to main content

Hyperstat IV Side Effects

Generic name: diazoxide

Medically reviewed by Drugs.com. Last updated on Apr 5, 2022.

Note: This document contains side effect information about diazoxide. Some dosage forms listed on this page may not apply to the brand name Hyperstat IV.

Applies to diazoxide: oral suspension.

Side effects include:

Sodium and fluid retention, tachycardia, palpitations, increased uric acid concentrations, hyperglycemia or glycosuria, GI intolerance, hirsutism, thrombocytopenia.

For Healthcare Professionals

Applies to diazoxide: compounding powder, injectable solution, oral capsule, oral suspension.

Cardiovascular

Angina with myocardial and cerebral infarction have been associated with the use of a 300 mg intravenous dose of diazoxide (the active ingredient contained in Hyperstat IV)

One case of optic nerve infarction was reported following a single 300 mg bolus dose of diazoxide, as a result of a sudden reduction in diastolic pressure.

Results from one prospective trial conducted in patients with severe hypertension and coronary artery disease showed a 50% incidence of ischemic changes in the electrocardiogram following single 300 mg bolus injections of diazoxide.[Ref]

Common (1% to 10%): Tachycardia, palpitations

Frequency not reported: Hypotension, transient hypertension, chest pain[Ref]

Nervous system

Frequency not reported: Transient loss of taste, headache, dizziness, polyneuritis, paresthesia, extrapyramidal signs[Ref]

Gastrointestinal

Frequency not reported: Nausea, vomiting, abdominal pain, ileus, diarrhea[Ref]

Metabolic

Sodium and fluid retention may precipitate congestive heart failure in patients with compromised cardiac reserve.[Ref]

Common (1% to 10%): Increased levels of serum uric acid

Frequency not reported: Sodium retention, fluid retention, diabetic ketoacidosis, hyperosmolar nonketotic coma, hyperglycemia, glycosuria, anorexia[Ref]

Respiratory

Frequency not reported: Pulmonary hypertension[Ref]

Other

Frequency not reported: Weakness, malaise, fever[Ref]

Hematologic

Frequency not reported: Thrombocytopenia with or without purpura, neutropenia, eosinophilia, decreased hemoglobin/hematocrit, excessive bleeding, azotemia, lymphadenopathy[Ref]

Immunologic

Frequency not reported: Decreased IgG, monilial dermatitis, herpes[Ref]

Musculoskeletal

Frequency not reported: Advance in bone age[Ref]

Ocular

Frequency not reported: Transient cataracts, subconjunctival hemorrhage, ring scotoma, blurred vision, diplopia, lacrimation[Ref]

Psychiatric

Frequency not reported: Anxiety, insomnia[Ref]

Genitourinary

Frequency not reported: Decreased urinary output, hematuria, albuminuria, galactorrhea, enlargement of lump in breast[Ref]

Hepatic

Frequency not reported: Increased AST, increased alkaline phosphatase[Ref]

Renal

Frequency not reported: Decreased creatinine clearance, reversible nephrotic syndrome[Ref]

Dermatologic

Frequency not reported: Hirsutism of lanugo type (mainly on the forehead, back, and limbs), skin rash, pruritus, loss of scalp hair[Ref]

Endocrine

Frequency not reported: Gout, acute pancreatitis/pancreatic necrosis[Ref]

Frequently asked questions

More about Hyperstat IV (diazoxide)

Patient resources

Other brands

Proglycem

Professional resources

Related treatment guides

References

1. "Product Information. Proglycem (diazoxide)." Teva Pharmaceuticals USA (2015):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.